Horalix at Techstars Founder Catalyst Global Demo Day 2025
NEWS | December 18, 2025 | Sarajevo, Bosnia and Herzegovina
Horalix presented its AI echocardiography platform at the Techstars Founder Catalyst Global Demo Day on December 18, 2025.
Short answer
On December 18, 2025, Horalix presented its AI-assisted echocardiography platform during the Techstars Startup Community Partnership Founder Catalyst Global Demo Day.
The presentation concluded a selective 10-week program connecting founders from Sarajevo, Bosnia and Herzegovina, and Omaha, Nebraska. Horalix used Demo Day to explain its clinical workflow, product strategy, market opportunity, and vision for AI-assisted cardiac ultrasound reporting.
Horalix joins the Techstars Founder Catalyst cohort
Horalix was selected for the Techstars Startup Community Partnership Founder Catalyst Fall 2025, a global, part-time pre-accelerator for early-stage founders.
The program connected Sarajevo and Omaha through:
- Weekly masterclasses
- Product and growth workshops
- Mentor meetings
- Strategic partner sessions
- Pitch coaching
- Founder collaboration
- Preparation for Global Demo Day
Techstars also included Horalix in its official announcement of the first Sarajevo–Omaha cohort, describing the company as an AI-powered echocardiography platform focused on view detection, cardiac measurements, and structured reporting.
What Horalix presented at Demo Day
The Horalix pitch focused on a specific clinical problem: echocardiography is valuable and widely used, but its post-acquisition workflow can remain repetitive and time-consuming.
After cardiac ultrasound images are acquired, healthcare teams may still need to:
- Review multiple views and video clips
- Perform or verify measurements
- Evaluate cardiac chambers and function
- Organize findings
- Prepare structured reports
- Complete physician review and sign-off
Horalix is developing AI-assisted echocardiography software to support suitable parts of this process.
The platform is designed to process DICOM studies, extract structured measurements, and prepare report-ready information while keeping clinicians responsible for verification and final clinical decisions.
The Horalix investment thesis
The presentation did not describe Horalix as simply another general-purpose “AI for healthcare” company.
The company’s thesis is more focused:
Clinical artificial intelligence becomes valuable when it solves a repeatable operational problem inside a clearly defined healthcare workflow.
Echocardiography fits that model because every study requires image review, measurements, interpretation, documentation, and sign-off.
Horalix is therefore building more than an individual machine-learning model. Its product direction includes:
- Medical imaging ingestion
- AI model orchestration
- Structured measurement output
- Visual verification
- Reporting workflows
- Hospital deployment
- Clinical user management
- Healthcare-system integration
This workflow-first approach is central to how Horalix presents itself to hospitals, partners, and investors.
Why Demo Day mattered
Demo Day required Horalix to communicate a complex medical technology product in clear commercial language.
The pitch had to answer:
- What problem is being solved?
- Who experiences that problem?
- Why is the workflow suitable for automation?
- How does the product fit into existing clinical practice?
- What makes the company more than an AI model?
- How can the technology scale across institutions?
- Why is the Horalix team capable of building it?
This process helped the team sharpen both its investor narrative and its product positioning.
What the Techstars program helped Horalix develop
Throughout the Founder Catalyst program, Horalix worked on:
- Explaining the product more clearly
- Defining the target customer
- Connecting clinical value with operational value
- Refining its business model
- Improving its investor pitch
- Identifying milestones needed for hospital adoption
- Building relationships in the international startup ecosystem
These lessons continue to influence how Horalix approaches product development, partnerships, fundraising, and international expansion.
Did Techstars invest in Horalix?
No.
The Founder Catalyst Fall 2025 program was a non-equity pre-accelerator and did not provide Techstars investment funding.
Participation should not be confused with joining a funded Techstars accelerator or becoming a Techstars portfolio company.
Horalix was selected for and completed the Founder Catalyst program, received access to its training and mentor network, and presented at Global Demo Day.
What happened after Demo Day?
Following the program, Horalix continued working on:
- Clinical product validation
- Hospital and clinic pilots
- International startup programs
- Strategic partnerships
- Technical development
- Investment readiness
- European market expansion
The company’s long-term objective remains building practical AI infrastructure for echocardiography teams rather than an isolated demonstration model.
Learn more about: